Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Description

Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.

Conditions

Bladder Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Condition
Bladder Cancer
Intervention / Treatment

-

Contacts and Locations

Washington

Sibley Memorial Hospital, Washington, District of Columbia, United States, 20016

Baltimore

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients undergoing TURBT for radiographic or cystoscopic positive tumor
  • * 18+ years old
  • * Upper tract evaluated using standard of care throughout duration of the study
  • * Induction intravesical therapy initiated within four weeks of TURBT
  • * Variant histology consisting of less than 50% urothelial carcinoma
  • * History, or current diagnosis, of upper tract tumor or muscle-invasive bladder cancer
  • * Prior history of pelvic radiation
  • * Active urinary tract infection (UTI)
  • * Patients who are noncompliant with the study protocol

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Armine Smith, MD, PRINCIPAL_INVESTIGATOR, Sibley Memorial Hospital

Study Record Dates

2028-01-04